<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3752">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581070</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE 20-01</org_study_id>
    <nct_id>NCT04581070</nct_id>
  </id_info>
  <brief_title>The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic&quot;</brief_title>
  <official_title>COVID-IYON Study. Prospective, Multisite, Descriptive, Observational Clinical/Epidemiological Study Examining Data Pertaining to Clinical Outcomes and Organizational Responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multisite, descriptive, observational clinical/epidemiological study&#xD;
      examining both quantitative and qualitative data pertaining to clinical outcomes and&#xD;
      organizational responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) pandemic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study collects real-time observational data regarding the impact of SARS-CoV-2 infection&#xD;
      on patients with cancer, and on the functioning and organisation of cancer and malignant&#xD;
      haematology services in the Republic of Ireland in response to the 2020 SARS-CoV-2 pandemic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>A qualitative description</measure>
    <time_frame>Up til 1 year</time_frame>
    <description>A qualitative narrative description of national cancer care practises and risk mitigation strategies adopted in response to the SARS-CoV-2 pandemic.</description>
  </primary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Cancer</condition>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under the care of medical oncology &amp; malignant haematology services, admitted at&#xD;
        participating sites, who test positive for SARS-CoV-2 infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18&#xD;
&#xD;
          2. Informed consent has been obtained.&#xD;
&#xD;
          3. Cytotoxic chemotherapy, targeted anticancer therapy, immunomodulatory anticancer&#xD;
             therapy, hormonotherapy, radiotherapy, oncologic surgery, or other anticancer&#xD;
             treatment within the last 12 months (ongoing and completed).&#xD;
&#xD;
          4. Tested positive for SARS-CoV-2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

